Approval was based on results from multiple studies, which demonstrated a slowing of cognitive decline in patients with ...

The Japanese and American based pharma companies announced a win for their Alzheimer’s treatment, which has faced some negative backlash over the last year.

Metsera, which is developing weight-loss drugs, said on Monday it is seeking a valuation of up to $1.78 billion in its U.S.

The FDA approves a new maintenance dosing regimen for lecanemab (Leqembi; Eisai) in patients with early-stage Alzheimer ...

With this approval, patients who receive the anti-amyloid drug biweekly for 18 months can then consider switching to a monthly dosing regimen.

Following a lawsuit filed last week, Sage has officially rejected Biogen’s unsolicited buyout offer, which valued the ...

Sage Therapeutics said on Monday that its board has unanimously rejected Biogen’s $469 million offer, stating it ...

Sage Therapeutics said on Monday that its board has unanimously rejected the takeover offer it received from Biogen. The ...

Sage Therapeutics Inc. rejected a takeover offer from drugmaker Biogen Inc. and said it has started exploring possible options including a sale.

Sage Therapeutics has rejected a buyout bid from partner Biogen and launched a review of strategic alternatives. Sage on Monday said its board determined that Biogen's $7.22-a-share proposal ...

Sage Therapeutics has rejected the unsolicited acquisition offer it received earlier this month from longtime partner Biogen ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.